Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold
作者:Siyuan Yin、Chunming Tang、Bin Wang、Ying Zhang、Liliang Zhou、Lingjing Xue、Can Zhang
DOI:10.1016/j.ejmech.2016.04.072
日期:2016.9
For the purpose of developing novel EGFR/HER2 tyrosine kinases inhibitors with high inhibition activity and low toxicity, two novel series of oxazolo[4,5-g]quinazolin-2(1H)-one derivatives as EGFR/HER2 dual inhibitors introducing two electrophiles 2-(2-bromoacetyl)ethyl and 2-(2-chloroacetoxy)ethyl group as side-chain at 1-position respectively and evaluated their EGFR and HER2 inhibition activity
为了开发具有高抑制活性和低毒性的新型EGFR / HER2酪氨酸激酶抑制剂,两个新系列的恶唑并[4,5- g ]喹唑啉-2(1H)-one衍生物作为EGFR / HER2双重抑制剂引入了两种亲电试剂以2-(2-溴乙酰基)乙基和2-(2-氯乙酰氧基)乙基为侧链,分别与拉帕替尼比较,评价其对EGFR和HER2的抑制活性和毒性。所有这些化合物均通过EGFR和HER2激酶抑制作用以及两种体外抗增殖试验进行了评估。大多数设计的化合物均表现出对EGFR和HER2的中等至高抑制活性。特别是化合物11o,11p,12e和12f表现出对EGFR和HER2的高度抑制作用。此外,化合物11p和12f对人肺腺癌细胞系(A549)和人乳腺癌细胞系(SK-Br3)的抗增殖活性也很好,而12f对人胚肺成纤维细胞的毒性最低。线(HELF)单元格。最后,在小鼠刘易斯肺癌(LLC)异种移植模型中,化合物12f表现出比拉帕替尼显着更高的对肿瘤生长的抑制作用。